Immunome, Inc. $IMNM Stock: Candriam S.C.A. Decreases Holdings

Candriam S.C.A. reduced its position in Immunome, Inc. (NASDAQ:IMNM) by 28.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 489,853 shares of the company’s stock after selling 190,279 shares during the period. Candriam S.C.A.’s holdings in Immunome were worth $10,575,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP bought a new position in Immunome during the 2nd quarter worth approximately $25,000. Integrated Wealth Concepts LLC bought a new stake in shares of Immunome in the 2nd quarter valued at approximately $27,000. Assetmark Inc. increased its holdings in shares of Immunome by 46.6% in the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after acquiring an additional 1,442 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Immunome by 0.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 188,636 shares of the company’s stock valued at $3,997,000 after acquiring an additional 1,625 shares in the last quarter. Finally, KBC Group NV acquired a new stake in shares of Immunome during the 1st quarter valued at approximately $60,000. 44.58% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Wedbush restated an “outperform” rating and set a $35.00 price objective on shares of Immunome in a research note on Tuesday, October 27th. HC Wainwright reiterated a “buy” rating on shares of Immunome in a research note on Tuesday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a report on Thursday, October 15th. Stifel Nicolaus assumed coverage on shares of Immunome in a research report on Wednesday, September 30th. They issued a “hold” rating and a $24.00 price target on the stock. Finally, Alliance Global Partners started coverage on Immunome in a research note on Monday, September 21st. They set a “buy” rating and a $32.00 price objective for the company. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.25.

Immunome Stock Performance

NASDAQ IMNM opened at $19.36 on Tuesday. Immunome, Inc. has a 1 year low of $15.46 and a 1 year high of $30.06. The business’s fifty day moving average is $21.33 and its two-hundred day moving average is $22.37. The stock has a market capitalization of $2.20 billion, a P/E ratio of -7.65 and a beta of 2.68.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.15). On average, research analysts forecast that Immunome, Inc. will post -2.48 earnings per share for the current year.

Insider Buying and Selling at Immunome

In related news, Director Isaac Barchas sold 11,048 shares of Immunome stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total value of $301,058.00. Following the transaction, the director owned 92,211 shares of the company’s stock, valued at approximately $2,512,749.75. This trade represents a 10.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 13,200 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the sale, the insider owned 65,050 shares in the company, valued at approximately $1,647,066. The trade was a 16.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 7.21% of the company’s stock.

About Immunome

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need.

The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.

Immunome became a publicly traded company in 2023 following a merger with Morphimmune and a combination with Ayala Pharmaceuticals.